Lattrich CR - Search Results

1

Resumption of Trastuzumab in Patients With Disease Recurrence After (Neo-) Adjuvant Anti-HER2-therapy in Patients With HER2-positive Breast Cancer.

Hanker LC, FÖrster F, SchrÖder J, Grafe A, Hitschold T, Hesse T, Lattrich CR, Rody A. Hanker LC, et al. Among authors: lattrich cr. Anticancer Res. 2020 Jul;40(7):3973-3981. doi: 10.21873/anticanres.14390. Anticancer Res. 2020. PMID: 32620640

2

Additive effects of trastuzumab and genistein on human breast cancer cells.

Lattrich C, Lubig J, Springwald A, Goerse R, Ortmann O, Treeck O. Lattrich C, et al. Anticancer Drugs. 2011 Mar;22(3):253-61. doi: 10.1097/CAD.0b013e3283427bb5. Anticancer Drugs. 2011. PMID: 21160418

3

Primary metastatic breast cancer in the era of targeted therapy - Prognostic impact and the role of breast tumour surgery.

Barinoff J, Schmidt M, Schneeweiss A, Schoenegg W, Thill M, Keitel S, Lattrich CR, Hinke A, Kutscheidt A, Jackisch C. Barinoff J, et al. Among authors: lattrich cr. Eur J Cancer. 2017 Sep;83:116-124. doi: 10.1016/j.ejca.2017.06.002. Epub 2017 Jul 20. Eur J Cancer. 2017. PMID: 28735068

4

Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor beta1.

Lattrich C, Juhasz-Boess I, Ortmann O, Treeck O. Lattrich C, et al. Oncol Rep. 2008 Mar;19(3):811-7. Oncol Rep. 2008. PMID: 18288420

5

Vaginal Estrogen Therapy for Patients with Breast Cancer.

Moegele M, Buchholz S, Seitz S, Lattrich C, Ortmann O. Moegele M, et al. Geburtshilfe Frauenheilkd. 2013 Oct;73(10):1017-1022. doi: 10.1055/s-0033-1350876. Geburtshilfe Frauenheilkd. 2013. PMID: 24771890 Free PMC article.

6

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.

Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Löhberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K. Fehm T, et al. Among authors: lattrich c. Breast Cancer Res Treat. 2010 Nov;124(2):403-12. doi: 10.1007/s10549-010-1163-x. Epub 2010 Sep 22. Breast Cancer Res Treat. 2010. PMID: 20859679 Clinical Trial.

7

Effects of a combined treatment with GPR30 agonist G-1 and herceptin on growth and gene expression of human breast cancer cell lines.

Lubig J, Lattrich C, Springwald A, Häring J, Schüler S, Ortmann O, Treeck O. Lubig J, et al. Cancer Invest. 2012 Jun;30(5):372-9. doi: 10.3109/07357907.2012.666690. Epub 2012 Apr 2. Cancer Invest. 2012. PMID: 22468845

8

GPR30 gene polymorphisms are associated with progesterone receptor status and histopathological characteristics of breast cancer patients.

Giess M, Lattrich C, Springwald A, Goerse R, Ortmann O, Treeck O. Giess M, et al. J Steroid Biochem Mol Biol. 2010 Jan;118(1-2):7-12. doi: 10.1016/j.jsbmb.2009.09.001. Epub 2009 Sep 8. J Steroid Biochem Mol Biol. 2010. PMID: 19744559

9

Icb-1 Gene expression is elevated in human endometrial adenocarcinoma and is closely associated with HER2 expression.

Springwald A, Lattrich C, Skrzypczak M, Goerse R, Ortmann O, Treeck O. Springwald A, et al. Cancer Invest. 2010 Nov;28(9):904-9. doi: 10.3109/07357907.2010.483511. Cancer Invest. 2010. PMID: 20569072

10

Single nucleotide polymorphisms in human gene icb-1 and breast cancer susceptibility.

Springwald A, Lattrich C, Seitz S, Ortmann O, Treeck O. Springwald A, et al. Cancer Invest. 2009 Jul;27(6):669-72. doi: 10.1080/07357900802620877. Cancer Invest. 2009. PMID: 19308812

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

40 results

Search Page